ES2895432T3 - Imatinib para uso en el tratamiento de accidente cerebrovascular - Google Patents
Imatinib para uso en el tratamiento de accidente cerebrovascular Download PDFInfo
- Publication number
- ES2895432T3 ES2895432T3 ES17760399T ES17760399T ES2895432T3 ES 2895432 T3 ES2895432 T3 ES 2895432T3 ES 17760399 T ES17760399 T ES 17760399T ES 17760399 T ES17760399 T ES 17760399T ES 2895432 T3 ES2895432 T3 ES 2895432T3
- Authority
- ES
- Spain
- Prior art keywords
- imatinib
- dose
- day
- administered
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000005517 L01XE01 - Imatinib Substances 0.000 title claims abstract description 142
- 229960002411 imatinib Drugs 0.000 title claims abstract description 138
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 title claims abstract description 134
- 238000011282 treatment Methods 0.000 title claims abstract description 55
- 208000006011 Stroke Diseases 0.000 title claims abstract description 29
- 230000002537 thrombolytic effect Effects 0.000 claims description 47
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 38
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 38
- 238000013151 thrombectomy Methods 0.000 claims description 30
- 229960000187 tissue plasminogen activator Drugs 0.000 claims description 26
- 108010039185 Tenecteplase Proteins 0.000 claims description 9
- 108010051412 reteplase Proteins 0.000 claims description 9
- 229960003318 alteplase Drugs 0.000 claims description 7
- 229960002917 reteplase Drugs 0.000 claims description 5
- 229960000216 tenecteplase Drugs 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 description 37
- 239000000243 solution Substances 0.000 description 33
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 28
- 208000032382 Ischaemic stroke Diseases 0.000 description 25
- 230000000694 effects Effects 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 13
- 208000032843 Hemorrhage Diseases 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 230000002411 adverse Effects 0.000 description 11
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 11
- 239000003826 tablet Substances 0.000 description 11
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 11
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 10
- 239000003146 anticoagulant agent Substances 0.000 description 10
- 206010061216 Infarction Diseases 0.000 description 8
- 208000007536 Thrombosis Diseases 0.000 description 8
- 230000007574 infarction Effects 0.000 description 8
- 206010048962 Brain oedema Diseases 0.000 description 7
- 208000006752 brain edema Diseases 0.000 description 7
- 101150046002 ced-1 gene Proteins 0.000 description 7
- 238000002591 computed tomography Methods 0.000 description 7
- 102000001301 EGF receptor Human genes 0.000 description 6
- 108060006698 EGF receptor Proteins 0.000 description 6
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 6
- 108091008606 PDGF receptors Proteins 0.000 description 6
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 6
- 230000002008 hemorrhagic effect Effects 0.000 description 6
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 6
- 230000036470 plasma concentration Effects 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 229940099983 activase Drugs 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 229960001346 nilotinib Drugs 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000000844 transformation Methods 0.000 description 5
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 101150055276 ced-3 gene Proteins 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 230000001934 delay Effects 0.000 description 4
- 229940080856 gleevec Drugs 0.000 description 4
- 238000002595 magnetic resonance imaging Methods 0.000 description 4
- 230000000926 neurological effect Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 229940113038 tnkase Drugs 0.000 description 4
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 3
- 108091008605 VEGF receptors Proteins 0.000 description 3
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 101150117572 ced-2 gene Proteins 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 239000003527 fibrinolytic agent Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000010410 reperfusion Effects 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 3
- SRSGVKWWVXWSJT-ATVHPVEESA-N 5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-n-(2-pyrrolidin-1-ylethyl)-1h-pyrrole-3-carboxamide Chemical compound CC=1NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C(C)C=1C(=O)NCCN1CCCC1 SRSGVKWWVXWSJT-ATVHPVEESA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 206010019013 Haemorrhagic infarction Diseases 0.000 description 2
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010037549 Purpura Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- 239000003819 Toceranib Substances 0.000 description 2
- 229940127218 antiplatelet drug Drugs 0.000 description 2
- 238000013176 antiplatelet therapy Methods 0.000 description 2
- 102000004441 bcr-abl Fusion Proteins Human genes 0.000 description 2
- 108010056708 bcr-abl Fusion Proteins Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000007894 caplet Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 102000045108 human EGFR Human genes 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 229960004891 lapatinib Drugs 0.000 description 2
- 206010034754 petechiae Diseases 0.000 description 2
- 238000011458 pharmacological treatment Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- -1 small-molecule tyrosine kinase inhibitor Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010002329 Aneurysm Diseases 0.000 description 1
- 208000022211 Arteriovenous Malformations Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000032862 Clinical Deterioration Diseases 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 1
- 206010028817 Nausea and vomiting symptoms Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 101150093908 PDGFRB gene Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229940124090 Platelet-derived growth factor (PDGF) receptor antagonist Drugs 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000005744 arteriovenous malformation Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 229960003736 bosutinib Drugs 0.000 description 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940125436 dual inhibitor Drugs 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 229940021013 electrolyte solution Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 1
- 229950008835 neratinib Drugs 0.000 description 1
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 229940090244 palladia Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 229940034785 sutent Drugs 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 229940069905 tasigna Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960005048 toceranib Drugs 0.000 description 1
- 229940094060 tykerb Drugs 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 229950000578 vatalanib Drugs 0.000 description 1
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1650260A SE539450C2 (en) | 2016-02-29 | 2016-02-29 | Imatinib for use in the treatment of stroke |
| PCT/SE2017/050183 WO2017151043A1 (en) | 2016-02-29 | 2017-02-27 | Imatinib for use in the treatment of stroke |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2895432T3 true ES2895432T3 (es) | 2022-02-21 |
Family
ID=59744327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17760399T Active ES2895432T3 (es) | 2016-02-29 | 2017-02-27 | Imatinib para uso en el tratamiento de accidente cerebrovascular |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10953010B2 (enExample) |
| EP (1) | EP3423060B1 (enExample) |
| JP (1) | JP6914957B2 (enExample) |
| CN (2) | CN119523986A (enExample) |
| AU (1) | AU2017227515B2 (enExample) |
| DK (1) | DK3423060T3 (enExample) |
| ES (1) | ES2895432T3 (enExample) |
| HR (1) | HRP20211621T1 (enExample) |
| HU (1) | HUE056798T2 (enExample) |
| LT (1) | LT3423060T (enExample) |
| PL (1) | PL3423060T3 (enExample) |
| PT (1) | PT3423060T (enExample) |
| RS (1) | RS62465B1 (enExample) |
| RU (1) | RU2739382C1 (enExample) |
| SE (1) | SE539450C2 (enExample) |
| SI (1) | SI3423060T1 (enExample) |
| WO (1) | WO2017151043A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10617756B2 (en) * | 2017-01-05 | 2020-04-14 | Shimojani, LLC | Drug regimen for treatment of cerebral ischemia |
| CN114306342B (zh) * | 2020-09-30 | 2024-06-28 | 江苏先声药业有限公司 | 一种注射用伊马替尼盐的药物组合物及其制备方法 |
| CN118524852A (zh) * | 2021-11-09 | 2024-08-20 | 真和制药有限公司 | 治疗或抑制心血管疾病的方法 |
| EP4311539A1 (en) | 2022-07-29 | 2024-01-31 | Artorange Ltd. | Imatinib formulation for parenteral administration |
| US20250000934A1 (en) | 2023-06-28 | 2025-01-02 | Pharmazz, Inc. | Lyophilized sovateltide-based injectable formulation and method for preparation thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY148074A (en) * | 2005-05-10 | 2013-02-28 | Novartis Ag | Pharmaceutical compositions comprising imatinib and a release retardant |
| EP2021028A2 (en) | 2006-04-17 | 2009-02-11 | Ludwig Institute For Cancer Research | Methods and compositions for modulation of blood-neural barrier |
| US7977348B2 (en) * | 2006-04-27 | 2011-07-12 | Sicor Inc. | Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α |
| EP2076507A2 (en) * | 2006-10-26 | 2009-07-08 | Sicor, Inc. | Imatinib base, and imatinib mesylate and processes for preparation thereof |
| US20100136094A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems for modulating inflammation |
| TR201911199T4 (tr) * | 2009-03-27 | 2019-08-21 | Moleac Pte Ltd | Hücre büyümesini arttırmak için tedavi. |
-
2016
- 2016-02-29 SE SE1650260A patent/SE539450C2/en not_active IP Right Cessation
-
2017
- 2017-02-27 CN CN202411509669.3A patent/CN119523986A/zh active Pending
- 2017-02-27 US US16/080,529 patent/US10953010B2/en active Active
- 2017-02-27 LT LTEPPCT/SE2017/050183T patent/LT3423060T/lt unknown
- 2017-02-27 SI SI201730931T patent/SI3423060T1/sl unknown
- 2017-02-27 HU HUE17760399A patent/HUE056798T2/hu unknown
- 2017-02-27 DK DK17760399.0T patent/DK3423060T3/da active
- 2017-02-27 HR HRP20211621TT patent/HRP20211621T1/hr unknown
- 2017-02-27 JP JP2018545843A patent/JP6914957B2/ja active Active
- 2017-02-27 RU RU2019122730A patent/RU2739382C1/ru active
- 2017-02-27 WO PCT/SE2017/050183 patent/WO2017151043A1/en not_active Ceased
- 2017-02-27 PL PL17760399T patent/PL3423060T3/pl unknown
- 2017-02-27 ES ES17760399T patent/ES2895432T3/es active Active
- 2017-02-27 CN CN201780013732.6A patent/CN108697711A/zh active Pending
- 2017-02-27 RS RS20211286A patent/RS62465B1/sr unknown
- 2017-02-27 PT PT177603990T patent/PT3423060T/pt unknown
- 2017-02-27 EP EP17760399.0A patent/EP3423060B1/en active Active
- 2017-02-27 AU AU2017227515A patent/AU2017227515B2/en active Active
-
2021
- 2021-02-26 US US17/186,303 patent/US20210236488A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PT3423060T (pt) | 2021-10-20 |
| RS62465B1 (sr) | 2021-11-30 |
| AU2017227515B2 (en) | 2022-03-24 |
| JP2019507165A (ja) | 2019-03-14 |
| SE539450C2 (en) | 2017-09-26 |
| LT3423060T (lt) | 2021-11-10 |
| CN108697711A (zh) | 2018-10-23 |
| RU2739382C1 (ru) | 2020-12-23 |
| JP6914957B2 (ja) | 2021-08-04 |
| CN119523986A (zh) | 2025-02-28 |
| EP3423060B1 (en) | 2021-07-21 |
| US10953010B2 (en) | 2021-03-23 |
| DK3423060T3 (da) | 2021-10-25 |
| SE1650260A1 (en) | 2017-08-30 |
| WO2017151043A1 (en) | 2017-09-08 |
| AU2017227515A1 (en) | 2018-08-30 |
| EP3423060A1 (en) | 2019-01-09 |
| SI3423060T1 (sl) | 2021-11-30 |
| US20210236488A1 (en) | 2021-08-05 |
| HUE056798T2 (hu) | 2022-03-28 |
| EP3423060A4 (en) | 2020-01-01 |
| US20190030030A1 (en) | 2019-01-31 |
| PL3423060T3 (pl) | 2022-01-10 |
| HRP20211621T1 (hr) | 2022-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2895432T3 (es) | Imatinib para uso en el tratamiento de accidente cerebrovascular | |
| ES2940669T3 (es) | Métodos de tratamiento de lesiones o afecciones relacionadas con edema del SNC | |
| Şenyüz et al. | Albendazole therapy in the treatment of hydatid liver disease | |
| Alamdarsaravi et al. | Efficacy and safety of celecoxib monotherapy for mild to moderate depression in patients with colorectal cancer: A randomized double-blind, placebo controlled trial | |
| EA032515B1 (ru) | Лечение или профилактика сердечно-сосудистых явлений с использованием колхицина | |
| ES2963348T3 (es) | Métodos para tratar la osificación heterotópica | |
| Balducci et al. | Palliative care in older patients with cancer | |
| WO2019126579A1 (en) | Colchicine formulations and methods of use | |
| Chamberlain | Intracerebral meningiomas | |
| Demarco et al. | Use of a hypodense sodium fluorescein solution for the endoscopic repair of rhinogenic cerebrospinal fluid fistulae | |
| Awad et al. | Dabigatran, intracranial hemorrhage, and the neurosurgeon | |
| PT1542700E (pt) | Método para prevenir ou reduzir fracturas secundárias após a fractura da anca | |
| CA2720670A1 (en) | Biological markers and response to treatment for pain, inflammation, neuronal or vascular injury and methods of use | |
| Wen et al. | CTNI-12. Preliminary results of the abemaciclib arm in the individualized screening trial of innovative glioblastoma therapy (INSIGHT): a phase II platform trial using Bayesian adaptive randomization | |
| Rahman et al. | CTNI-11. CC-115 in newly diagnosed MGMT unmethylated glioblastoma in the individualized screening trial of innovative Glioblastoma therapy (insight): a phase II randomized bayesian adaptive platform trial | |
| ES2668943T3 (es) | Composición farmacéutica para tratar eyaculación precoz y método de tratamiento de la eyaculación precoz | |
| Pak et al. | Pseudoaneurysm as a late complication of gamma knife surgery for trigeminal neuralgia | |
| JP2023549086A (ja) | デビミスタットを使用して胆道癌を治療するための治療法及び組成物 | |
| Assietti et al. | Intra-arterial cisplatin in malignant brain tumors: incidence and severity of otic toxicity | |
| Malik et al. | Laparoscopic versus conventional surgery for hepatic hydatid disease: a comparative study | |
| Jain | HBO Therapy in Neurosurgery | |
| Steglatro | New Drug Approvals | |
| Cher et al. | CTNI-14. A 3-ARM, PHASE IIA TRIAL OF SAFETY & EFFICACY OF OLINVACIMAB, A MONOCLONAL ANTIBODY TO VEGFR2 IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME WITH IMAGING AND PK/PD ASSESSMENTS | |
| ALLAM | WCN23-0127 KIDNEY OUT COMES IN SUDANSES CHILDREN WITH LUPUS NEPHRITIES | |
| Reyna et al. | The management of pain and other complications from bone metastases |